Patients who were >7.5 years of age at diagnosis (the median age at diagnosis) more often had three to five reported exposures compared with younger patients (P = 0.027; OR 3.7; 95% CI 1.3,10.6; Table 2 ), and patients with anti-SRP autoantibody more often had three to five exposures compared with patients without a myositis autoantibody (P = 0.027; OR = 31.0; 95% CI 1.9, 507). Patients with a longer delay to diagnosis (>4 months, the median delay) were more likely to have three to five exposures than patients with a shorter delay (P = 0.034; OR 3.4; 95% CI 1. 2, 9.8) . There were no other significant differences in the frequency or number of noted exposures between clinical phenotypes [JDM vs juvenile PM (JPM)], nor by gender, disease course, delay to diagnosis or between other autoantibody phenotypes (data not shown).